#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Hla Ii

This article discusses several clinical trials investigating the use of Specific Nucleic Acid SNA-HLA II, a component found in various drug formulations, for treating different medical conditions. These trials aim to evaluate the efficacy and safety of medications containing this substance in addressing issues such as genital HPV infections, Epstein-Barr Virus (EBV) infections, herpes infections, and non-genital warts.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-HLA II?

SPECIFIC NUCLEIC ACID SNA-HLA II is a unique medical compound that is being studied for its potential to treat various health conditions. It is also known as SNA-HLA II or SPECIFIC NUCLEIC ACID – HUMAN LEUCOCYTE ANTIGEN TYPE II[1]. This substance is a type of nucleic acid, which is a fundamental building block of our genetic material.

Conditions Treated

Research is ongoing to evaluate the effectiveness of SNA-HLA II in treating several conditions, including:

  • Human Papillomavirus (HPV) infections: This includes genital HPV infections and non-genital warts[1][4]
  • Epstein-Barr Virus (EBV) infections: This virus is known to cause mononucleosis and is associated with chronic fatigue[2]
  • Herpes Simplex Virus (HSV) infections: Particularly recurrent orofacial herpes infections (cold sores)[3]

How It Works

While the exact mechanism of action is still being studied, SNA-HLA II is believed to work by interacting with the immune system. It is often used in combination with other substances such as:

  • Interferon alfa: A protein that helps fight viral infections
  • Interleukin-1 and Interleukin-2: Proteins that help regulate immune responses
  • Ribonucleic acid (RNA): Another type of nucleic acid involved in various biological processes
  • Other specific nucleic acids targeted at particular viruses (e.g., SNA-PAPI for HPV, SNA-EBV for Epstein-Barr virus)[1][2][3][4]

Ongoing Research

Several clinical trials are currently underway to evaluate the effectiveness of treatments containing SNA-HLA II:

  • A study on clearing genital HPV infections using a combination including SNA-HLA II (2LPAPI)[1]
  • Research on reducing fatigue in patients with Epstein-Barr virus infection using treatments containing SNA-HLA II (2LEBV and 2LXFS)[2]
  • A trial evaluating the effectiveness of a treatment containing SNA-HLA II (2LHERP) in patients with recurrent orofacial herpes infections[3]
  • A study on treating non-genital warts using medications that include SNA-HLA II (2LVERU JUNIOR and 2LVERU)[4]

Potential Benefits

The ongoing research aims to determine if treatments containing SNA-HLA II can provide benefits such as:

  • Clearing or reducing viral infections
  • Decreasing the frequency of symptom recurrence
  • Reducing the severity and duration of symptoms
  • Improving quality of life for patients with chronic viral infections

Safety and Side Effects

As with any medical treatment, safety is a primary concern in the ongoing studies. The clinical trials are designed to monitor for any adverse events or side effects. Patients with certain conditions, such as severe immune deficiencies, are typically excluded from these studies to ensure participant safety[1][2][3][4].

It’s important to note that these treatments are still in the research phase. Patients should always consult with their healthcare providers before considering any new treatments.

Trial Focus Drug Name Main Objective Key Inclusion Criteria Primary Endpoint
Genital HPV infections 2LPAPI Evaluate efficacy on clearance of genital HR-HPV infections after 12 months Women 25-45 years with HR-HPV diagnosis HR-HPV infection clearance at 12-month visit
EBV infection and fatigue 2LEBV and 2LXFS Compare efficacy on fatigue severity at end of treatment Patients ≥12 years with significant fatigue and positive EBV serology General fatigue scale of MFI-20 questionnaire at 6-month visit
Recurrent orofacial herpes 2LHERP Evaluate efficacy on reducing number of recurrent episodes at 12 months Patients 16-80 years with ≥6 episodes in past 12 months Change in number of episodes at 12 months compared to baseline
Non-genital warts 2LVERU JUNIOR and 2LVERU Compare efficacy on wart disappearance at end of treatment (6 months) Patients ≥3 years with common, plantar, or flat warts Disappearance of warts at 6-month visit

FAQ

  • What is Specific Nucleic Acid SNA-HLA II? Specific Nucleic Acid SNA-HLA II is a type of nucleic acid that targets Human Leucocyte Antigen Type II. It is being studied as a component in various drug formulations for treating different viral infections and related conditions.
  • What conditions are being studied using drugs containing Specific Nucleic Acid SNA-HLA II? The clinical trials are investigating its use in treating genital HPV infections, Epstein-Barr Virus (EBV) infections, recurrent orofacial herpes infections, and non-genital warts.
  • How is the drug administered in these trials? In all the mentioned trials, the drugs containing Specific Nucleic Acid SNA-HLA II are administered as granules in capsules to be opened, with the route of administration being oromucosal use.
  • What is the duration of treatment in these clinical trials? The maximum treatment period mentioned in the trials is 6 months, with follow-up assessments often conducted at various intervals, including at 12 months in some studies.
  • Are there any common side effects or safety concerns mentioned? While specific side effects are not detailed, all trials include monitoring for adverse events (AEs) and serious adverse events (SAEs) as part of their safety assessments. Patients with severe immunodeficiency or those undergoing certain treatments are generally excluded from these trials.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Hla Ii

  • Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Romania

  • Study on the Effectiveness of Interferon Alfa, Interleukin-1, and Interleukin-2 in Treating Non-Genital Warts in Patients

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effectiveness of 2LHERP in Reducing Recurrent Cold Sores in Patients with Frequent Outbreaks

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Specific Nucleic Acid SNA-HLA II: A type of nucleic acid that targets Human Leucocyte Antigen Type II, being studied as a component in various drug formulations for treating different viral infections and related conditions.
  • Human Papillomavirus (HPV): A group of viruses that can cause various types of infections, including genital warts and certain cancers.
  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain types of cancer.
  • Orofacial herpes: A viral infection causing cold sores or fever blisters, typically around the mouth or on the face.
  • Verruca vulgaris: The medical term for common warts, which are small, rough growths on the skin caused by the human papillomavirus (HPV).
  • Verruca plantaris: The medical term for plantar warts, which are warts that occur on the soles of the feet.
  • Verruca plana: The medical term for flat warts, which are smoother and flatter than other types of warts.
  • Oromucosal use: A method of drug administration where the medication is applied to or absorbed through the mucous membrane of the mouth.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Events (SAEs): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or requires intervention to prevent permanent impairment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lpapi-with-interferon-alfa-in-clearing-genital-hpv-infections-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lherp-in-reducing-recurrent-cold-sores-in-patients-with-frequent-outbreaks/
  4. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-interferon-alfa-interleukin-1-and-interleukin-2-in-treating-non-genital-warts-in-patients/